Analyst firms · Morgan Stanley · LH

Morgan Stanley LH price target and rating history

Labcorp Holdings Inc. (LH) · Health Care

Morgan Stanley rates Labcorp Holdings Inc. (LH) Overweight with a $300 price target, as of its latest action on Aug 22, 2022. It has published 5 rating actions on LH since August 2021, including 0 upgrades and 0 downgrades.

Current rating
Overweight
Price target
$300
Median target, all firms
Too few
Actions on LH
5

Morgan Stanley price target on LH

$380$340$30020222023202420252026
Morgan Stanley price target on LH, each point a stated target, August 2021 to August 2022.

Every Morgan Stanley rating on LH

Questions about Morgan Stanley and LH

What is Morgan Stanley's price target for LH?
Morgan Stanley's latest stated price target for Labcorp Holdings Inc. (LH) is $300, from its action on Aug 22, 2022.
What is Morgan Stanley's rating on LH?
Morgan Stanley rates LH Overweight, a bullish rating, as of Aug 22, 2022.
When did Morgan Stanley last change its view on LH?
On Aug 22, 2022, Morgan Stanley resumes coverage at Overweight, price target $300.

More LH rating histories

All Morgan Stanley ratingsLH news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.